News & Updates
Filter by Specialty:
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
17 Jul 2023
Patient preferences must be considered for anticoagulation duration in unprovoked VTE
Shared decision making should be practiced by clinicians to include patient preferences and values when taking into account the duration of anticoagulant therapy for unprovoked venous thromboembolism (VTE), suggests a study.
Patient preferences must be considered for anticoagulation duration in unprovoked VTE
14 Jul 2023
Can cuffless wearable devices track BP changes?
A cuffless wearable device may help improve hypertension management if it demonstrates accuracy and clinical utility. However, a recent study has found that a commercially available blood pressure (BP) monitoring device does not accurately track night-time BP decline and medication-induced BP changes.
Can cuffless wearable devices track BP changes?
13 Jul 2023
Urinary CKD273 predicts early renal damage in primary hypertension
A classifier developed based on 273 urinary peptides (CKD273) can predict new-onset proteinuria in patients with primary hypertension and be used to diagnose those with early renal injury, reports a study. This predictor contributes to the early prevention and treatment of hypertensive nephropathy.
